Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.76 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14601865 | 0.87 | CHRM2 (0.71) | ACHECHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL14601864 | 0.83 | ACHE (0.74) | ACHE | |
| SCHEMBL12013902 | 0.81 | ACHE (0.75) | ACHECHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL14601867 | 0.81 | ACHE (0.71) | ACHE | |
| SCHEMBL8445224 | 0.81 | CHRM1 (0.74) | ACHECHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL14601856 | 0.79 | ACHE (0.67) | ACHE | |
| SCHEMBL4501370 | 0.78 | ACHE (0.81) | ACHE | |
| Oxalic Acid SCHEMBL7829511 | 0.75 | CHRM2 (0.52) | ACHECHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8825219 | 0.75 | ACHE (0.81) | ACHE | |
| SCHEMBL15599155 | 0.74 | ACHE (0.74) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021397-A1 | Neurocyte protective agent | EISAI CO., LTD. (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20070021397-A1 | Neurocyte protective agent | EISAI CO., LTD. (JP) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021397-A1 | Neurocyte protective agent | CHAT, GAP43, NES | ACHE 6/4885CHRM2 374/4885CHRM4 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.